This week, the Louisiana Office of Public Health (OPH) received a limited supply of approximately 160 treatment courses of remdesivir, which was donated by Gilead Sciences, Inc. and distributed to the state through the U.S. Department of Health and Human Services. Remdesivir has recently gained emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in treating hospitalized patients with Coronavirus.

OPH plans to distribute remdesivir to each tier 1 hospital with 5 or more current COVID-19 cases according to the allocation spreadsheet. If your hospital is on the list, you will automatically be sent the remdesivir from Morris and Dixon (M&D). OPH provided a memo with instructions on the M&D process, key inclusion/exclusion criteria, and an M&D contact who can answer questions.

Below are links that are mentioned in the scanned memo:
- Inclusion and Exclusion Criteria for Moderate Disease
- Inclusion and Exclusion Criteria for Severe Disease
- Fact Sheet for Health Care Providers: EUA of Remdesivir, which also includes instructions for reporting adverse events to the FDA MedWatch.

In addition, a pharmacy guide is available to assist providers and hospital pharmacies in identifying patients and appropriate drug administration.

If you have any questions, contact LHA Vice President of Member Services & Quality Improvement Kenneth Alexander at 225-928-0026 or kalexander@lhaonline.org.

Note: This Alert is being distributed to hospital C-Suite personnel in the LHA database.

This and other local, state and national hospital-specific resources and guidance from trusted sources can be found on the LHA's COVID-19 webpage.